Matches in SemOpenAlex for { <https://semopenalex.org/work/W122804489> ?p ?o ?g. }
- W122804489 endingPage "124" @default.
- W122804489 startingPage "93" @default.
- W122804489 abstract "It took over a century to validate what Behring [153] and Ehrlich [154] have reasoned and predicted of the potential clinical use of antibody-mediated therapies against infectious diseases and cancer. However, the practical application of antibody-mediated therapies was only possible several decades later. Porter [155] and Edelman et al. [156] published the molecular structure of the immunoglobulin molecule and through the ingenuity of Kohler and Milstein they engineered the production of hybridoma cell lines capable of producing monoclonal antibodies (mAbs). Such mAbs are one of the most important and fastest growing classes of therapeutic drugs in the treatment of non-malignant and malignant diseases. The first FDA approved cancer therapeutic antibody was in 1997 for the treatment of B-Non-Hodgkin Lymphoma (B-NHL). The mAb is a chimeric anti-CD20 mAb, rituximab, which targets both non-malignant and malignant B cells. Rituximab is currently the standard therapy when used in combination with chemotherapy (CHOP). However, like other therapeutics, a subset of patients initially does not respond and a subset responding patients develops resistance to further treatments. Such patients are in an urgent need of novel therapies to reverse resistance. This review will cover rituximab as a therapeutic prototype mAb for analyses of its several modes of action on sensitive and resistant B-NHL tumor cells, its chemo-immuno-sensitizing effects and applications of various means to reverse resistance through the use of small molecule inhibitors targeting members of the constitutively overactivated survival/antiapoptotic pathways." @default.
- W122804489 created "2016-06-24" @default.
- W122804489 creator A5055490703 @default.
- W122804489 date "2013-01-01" @default.
- W122804489 modified "2023-09-23" @default.
- W122804489 title "Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype" @default.
- W122804489 cites W1489062930 @default.
- W122804489 cites W1509374036 @default.
- W122804489 cites W1539571840 @default.
- W122804489 cites W1560571961 @default.
- W122804489 cites W1589026573 @default.
- W122804489 cites W1594335059 @default.
- W122804489 cites W161930446 @default.
- W122804489 cites W1755870104 @default.
- W122804489 cites W1854005499 @default.
- W122804489 cites W1893454428 @default.
- W122804489 cites W1915689252 @default.
- W122804489 cites W1938103646 @default.
- W122804489 cites W1963879883 @default.
- W122804489 cites W1965098193 @default.
- W122804489 cites W1965962344 @default.
- W122804489 cites W1965985271 @default.
- W122804489 cites W1967283758 @default.
- W122804489 cites W1972508039 @default.
- W122804489 cites W1975889968 @default.
- W122804489 cites W1976382352 @default.
- W122804489 cites W1979419663 @default.
- W122804489 cites W1979840572 @default.
- W122804489 cites W1984545880 @default.
- W122804489 cites W1984789674 @default.
- W122804489 cites W1990016924 @default.
- W122804489 cites W1990827960 @default.
- W122804489 cites W1990892742 @default.
- W122804489 cites W1992361007 @default.
- W122804489 cites W1996918021 @default.
- W122804489 cites W1998867518 @default.
- W122804489 cites W2002161324 @default.
- W122804489 cites W2002480447 @default.
- W122804489 cites W2002711015 @default.
- W122804489 cites W2003982318 @default.
- W122804489 cites W2007436659 @default.
- W122804489 cites W2009512645 @default.
- W122804489 cites W2010053288 @default.
- W122804489 cites W2010244981 @default.
- W122804489 cites W2012012527 @default.
- W122804489 cites W2016904449 @default.
- W122804489 cites W2018983670 @default.
- W122804489 cites W2022588086 @default.
- W122804489 cites W2024066199 @default.
- W122804489 cites W2024663996 @default.
- W122804489 cites W2026038242 @default.
- W122804489 cites W2027374210 @default.
- W122804489 cites W2027880707 @default.
- W122804489 cites W2029915215 @default.
- W122804489 cites W2030522563 @default.
- W122804489 cites W2031552402 @default.
- W122804489 cites W2032423298 @default.
- W122804489 cites W2032454178 @default.
- W122804489 cites W2034371559 @default.
- W122804489 cites W2035277855 @default.
- W122804489 cites W2036251477 @default.
- W122804489 cites W2037044333 @default.
- W122804489 cites W2037159578 @default.
- W122804489 cites W2040426470 @default.
- W122804489 cites W2043180462 @default.
- W122804489 cites W2044360617 @default.
- W122804489 cites W2044708061 @default.
- W122804489 cites W2045576568 @default.
- W122804489 cites W2045752058 @default.
- W122804489 cites W2046516922 @default.
- W122804489 cites W2049057915 @default.
- W122804489 cites W2049439131 @default.
- W122804489 cites W2049680978 @default.
- W122804489 cites W2050243165 @default.
- W122804489 cites W205637700 @default.
- W122804489 cites W2057796652 @default.
- W122804489 cites W2061611744 @default.
- W122804489 cites W2063157305 @default.
- W122804489 cites W2063317245 @default.
- W122804489 cites W2065757905 @default.
- W122804489 cites W2066485964 @default.
- W122804489 cites W2066823421 @default.
- W122804489 cites W2068033067 @default.
- W122804489 cites W2069075668 @default.
- W122804489 cites W2071843268 @default.
- W122804489 cites W2074143701 @default.
- W122804489 cites W2077115276 @default.
- W122804489 cites W2079756029 @default.
- W122804489 cites W2080501134 @default.
- W122804489 cites W2082369882 @default.
- W122804489 cites W2083459673 @default.
- W122804489 cites W2084884163 @default.
- W122804489 cites W2087175804 @default.
- W122804489 cites W2087776711 @default.
- W122804489 cites W2088332148 @default.
- W122804489 cites W2091031775 @default.
- W122804489 cites W2092425120 @default.
- W122804489 cites W2096617375 @default.